Governments have decided they will pay any price in the fight against COVID-19 while the pharmaceutical sector is already grappling with supply. Nobody should expect the PBS in 2021, 2022 or beyond to look like it does in 2020 - and that is before you even consider the long-term budgetary impact of the shock about to hit the economy.
This is just the start of a challenge that will almost certainly leave a permanent 'scar'
March 21, 2020 Latest NewsComment
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News


